Showing 15 posts of 1050 posts found.


How COVID-19 has affected the oncology drugs market

January 25, 2021
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Cancer

In its disruption to clinical trials and drug supply to patients, the COVID-19 pandemic has impacted the most crucial areas …


FDA approves Exelixis’ cancer drug Cabometyx

January 25, 2021
Sales and Marketing Cancer, Exelixis

The FDA has approved Exelixis’ Cabometyx (cabozantinib) for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in …

NICE recommends cutting-edge lymphoma treatment for NHS use

January 19, 2021
Manufacturing and Production Cancer, NICE

NHS clinicians in England will be able to consider a cutting-edge cancer treatment for some patients with a form of …


AstraZeneca’s Imfinzi gets EU and UK approval for new dosing option

January 15, 2021
Medical Communications AstraZeneca, Cancer, Imfinzi

AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU and the UK for an additional dosing option in locally advanced, …

NICE recommends GSK’s ZEJULA for advanced ovarian cancer

January 15, 2021
Medical Communications Cancer, GlaxoSmithKline, NICE

NICE has recommended the use of GlaxoSmithKline’s ZEJULA (niraparib) on the NHS in England for adult women with advanced high-grade …

UroGen and MD Anderson to collaborate on bladder cancer treatment

January 14, 2021
Cancer, UroGen Pharma

UroGen Pharma, a biopharmaceutical company dedicated to treating specialty cancers and urologic diseases, and The University of Texas MD Anderson …


BeiGene’s tislelizumab gets China approval for non-small cell lung cancer

January 14, 2021
BeiGene, Cancer, tislelizumab

BeiGene Ltd has announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) …


Novartis and BeiGene join forces to develop cancer drug tislelizumab

January 12, 2021
Manufacturing and Production BeiGene, Cancer, Novartis

Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene Ltd in major markets outside of China, accelerating …

Boehringer Ingelheim and Enara Bio to collaborate on cancer immunotherapies

January 12, 2021
Manufacturing and Production Boehringer Ingelheim, Cancer, Enara Bio

Boehringer Ingelheim and Enara Bio have entered into a strategic collaboration and licensing agreement to research and develop novel targeted …

Promising new treatment for drug-resistant prostate cancer

January 12, 2021
Manufacturing and Production Cancer

A new experimental drug could offer a promising treatment strategy for men with advanced, drug-resistant prostate cancer, researchers have said. …


Genentech’s cancer drug gets Breakthrough Therapy Designation from FDA

January 5, 2021
Manufacturing and Production Cancer, Genentech

Genentech has announced that tiragolumab, a novel cancer immunotherapy designed to bind to T cell immunoreceptor with Ig and ITIM …

Scientists develop new drug to target KRAS mutations in cancer

January 5, 2021
Manufacturing and Production Cancer, Cancer Research UK

In a study funded by Cancer Research UK and Wellcome, scientists have developed a new drug that effectively targets the …

BioInvent receives $3m payment for antibodies selected by Pfizer

December 23, 2020
Research and Development BioInvent, Cancer, Pfizer

BioInvent International, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, …


AstraZeneca’s cancer drug Tagrisso gets FDA approval

December 21, 2020
Sales and Marketing AstraZeneca, Cancer, FDA

The FDA has approved AstraZeneca’s Tagrisso (osimertinib) for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated …

NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer

November 5, 2020
Sales and Marketing BMS, Cancer, NHS, NICE, opdivo

NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for …

Latest content